Literature DB >> 6824255

Estrogen replacement therapy: indications and complications.

H L Judd, D R Meldrum, L J Deftos, B E Henderson.   

Abstract

Estrogen replacement therapy is one of the most controversial issues in the field of reproductive medicine. Indications for its use include hot flashes, vaginal atrophy, and risk of osteoporosis. Risk of heart disease may also be an indication but this use has not been firmly established. The role of estrogen replacement therapy in aging changes of skin needs clarification. Complications of therapy include endometrial cancer, breast cancer, hypertension, hyperlipidemia, and gallbladder disease. The last three complications presumably result from hepatic actions of estrogen replacement therapy.

Entities:  

Keywords:  Biology; Breast Cancer; Cancer; Cardiovascular Effects; Conferences And Congresses; Diseases; Endocrine System; Endometrial Cancer; Estrogens--administraction and dosage; Estrogens--complications; Estrogens--indications; Estrogens--pharmacodynamics; Hormone Receptors; Hormones; Lipid Metabolic Effects; Lipids; Menopause; Neoplasms; Ovary; Physiology; Reproduction; Treatment

Mesh:

Substances:

Year:  1983        PMID: 6824255     DOI: 10.7326/0003-4819-98-2-195

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  13 in total

1.  Effect of 17beta-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17beta-estradiol serum kinetics and bone mass in rats.

Authors:  F Bauss; A Esswein; K Reiff; G Sponer; B Müller-Beckmann
Journal:  Calcif Tissue Int       Date:  1996-09       Impact factor: 4.333

2.  Post-menopausal Osteoporosis: Can it Be Prevented?

Authors:  J P Wade; E F Vreede-Brown
Journal:  Can Fam Physician       Date:  1990-03       Impact factor: 3.275

3.  Translating safety, efficacy and compliance into economic value for controlled release dosage forms.

Authors:  M P Cramer; S R Saks
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

Review 4.  Overview of osteoporosis.

Authors:  B L Riggs
Journal:  West J Med       Date:  1991-01

5.  Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin.

Authors:  Robert H Boone; Angela M Cheung; Larisa M Girlan; E Jenny Heathcote
Journal:  Dig Dis Sci       Date:  2006-06       Impact factor: 3.199

6.  Continual naringin treatment benefits the recovery of traumatic brain injury in rats through reducing oxidative and inflammatory alterations.

Authors:  Qun-jian Cui; Li-yi Wang; Zhi-xuan Wei; Wen-sheng Qu
Journal:  Neurochem Res       Date:  2014-04-13       Impact factor: 3.996

7.  ADFR therapy in the prevention of bone loss after menopause.

Authors:  R Pérez Cano; R Moruno; M J Montoya; M A Vazquez; F Galán; M Garrido
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

8.  Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

Authors:  L J Black; M Sato; E R Rowley; D E Magee; A Bekele; D C Williams; G J Cullinan; R Bendele; R F Kauffman; W R Bensch
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

9.  Transdermal estroprogestins versus transdermal estrogen plus oral dihydrogesterone replacement in menopause.

Authors:  D Marchesoni; M Dal Pozzo; L Dal Magro; D M Paternoster; E Ferroni; T Maggino; C Romagnolo; B Mozzanega
Journal:  J Endocrinol Invest       Date:  1996-05       Impact factor: 4.256

10.  Osteoporosis: regulatory view.

Authors:  S Sobel
Journal:  Public Health Rep       Date:  1987 Jul-Aug       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.